{
  "docId": "019de073-a59c-77cf-8e75-229e6c5c9530",
  "docSlug": "74412512a1adb89488775a4a2b6a1b7b",
  "documentTitle": "Avenue Therapeutics | IPO Presentation Deck | 30 slides",
  "authorId": "avenue-therapeutics",
  "authorName": "Avenue Therapeutics",
  "documentKindSlug": "regulatory-filing",
  "documentKindLabel": "Regulatory filing",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 24,
  "pageCount": 30,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "timeline",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/24",
  "deckHref": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530",
  "deckJsonHref": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json",
  "deckAnchorHref": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.9,
        "x": 0.05,
        "y": 0.75
      },
      "kind": "callout",
      "text": "The Company intends to continue the dialogue with the FDA and submit a detailed protocol to gain alignment on a single safety study – the outcomes of this study could form the basis for resubmission of the NDA for IV tramadol",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8057b116-f7b4-4a79-9584-03e41fc578af",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "diagram",
      "text": "2019, 2021, 2022",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "27d767ad-9e3c-4dbb-9a0d-ab389fe7cd73",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.15,
        "y": 0.92
      },
      "kind": "disclaimer",
      "text": "Additional details on the history of regulatory interactions, decisions, and meetings between Avenue and the FDA are available in our public filings with the Securities and Exchange Commission",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f769b8ae-6bd9-4ae7-88f1-21b13cd265ad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.28,
        "x": 0.35,
        "y": 0.3
      },
      "kind": "list",
      "text": "February 2021: Resubmission. June 14, 2021: Second CRL regarding opioid stacking safety data.",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1c26fa6e-6056-4b12-88bb-a7df7363d95d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.65,
        "y": 0.3
      },
      "kind": "list",
      "text": "August 9, 2022: FDA meeting on study design for opioid stacking. FDA indicated proposed study design is reasonable.",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4bb4cdcc-c75f-480a-83a6-7b7383673a76",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.28,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "list",
      "text": "December 2019: NDA submission and October 2020 CRL.",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d99cb269-0470-4b0c-90e1-9ec97358a4f4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "Regulatory history and now a path forward for IV Tramadol NDA",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "19eafd50-a3c2-4d26-9bcb-70fb470340c9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "d529b528-b335-4eb5-ad25-224ed84c38ad",
      "evidence": "Chronological presentation of regulatory events",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}